Illumina, Amgen Collaborating on NGS-Based CDx for Colorectal Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina and Amgen will collaborate on the development of a next-generation sequencing-based companion diagnostic for the colorectal cancer drug Vectibix (panitumumab), the companies announced yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.